360 related articles for article (PubMed ID: 26631237)
1. Combined Angiotensin Receptor Modulation in the Management of Cardio-Metabolic Disorders.
Paulis L; Foulquier S; Namsolleck P; Recarti C; Steckelings UM; Unger T
Drugs; 2016 Jan; 76(1):1-12. PubMed ID: 26631237
[TBL] [Abstract][Full Text] [Related]
2. Recent changes in the landscape of combination RAS blockade.
Epstein BJ; Smith SM; Choksi R
Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
[TBL] [Abstract][Full Text] [Related]
3. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
4. Blocking the renin-angiotensin system: dual- versus mono-therapy.
Ravandi A; Teo KK
Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin II type 1 receptor antagonists in animal models of vascular, cardiac, metabolic and renal disease.
Michel MC; Brunner HR; Foster C; Huo Y
Pharmacol Ther; 2016 Aug; 164():1-81. PubMed ID: 27130806
[TBL] [Abstract][Full Text] [Related]
6. Importance of AT1 and AT2 receptors in the nucleus of the solitary tract in cardiovascular responses induced by a high-fat diet.
Speretta GF; Ruchaya PJ; Delbin MA; Melo MR; Li H; Menani JV; Sumners C; Colombari E; Bassi M; Colombari DSA
Hypertens Res; 2019 Apr; 42(4):439-449. PubMed ID: 30631157
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
Grothusen A; Divchev D; Luchtefeld M; Schieffer B
Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
[TBL] [Abstract][Full Text] [Related]
8. Rationale for combining blockers of the renin-angiotensin system.
Azizi M; Wuerzner G
Semin Nephrol; 2007 Sep; 27(5):544-54. PubMed ID: 17868792
[TBL] [Abstract][Full Text] [Related]
9. Role of the central renin‑angiotensin system in hypertension (Review).
Su C; Xue J; Ye C; Chen A
Int J Mol Med; 2021 Jun; 47(6):. PubMed ID: 33846799
[TBL] [Abstract][Full Text] [Related]
10. ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET.
Schindler C
Ther Adv Cardiovasc Dis; 2008 Aug; 2(4):233-48. PubMed ID: 19124424
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin II type 2 receptor (AT2R) in renal and cardiovascular disease.
Chow BS; Allen TJ
Clin Sci (Lond); 2016 Aug; 130(15):1307-26. PubMed ID: 27358027
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin II type 2 receptors contribute to vascular responses in spontaneously hypertensive rats treated with angiotensin II type 1 receptor antagonists.
Cosentino F; Savoia C; De Paolis P; Francia P; Russo A; Maffei A; Venturelli V; Schiavoni M; Lembo G; Volpe M
Am J Hypertens; 2005 Apr; 18(4 Pt 1):493-9. PubMed ID: 15831358
[TBL] [Abstract][Full Text] [Related]
13. Renin inhibition--benefit beyond hypertension control.
Kher V
J Assoc Physicians India; 2009 Jul; 57():518-20, 525. PubMed ID: 20329413
[TBL] [Abstract][Full Text] [Related]
14. [The future of renin inhibition].
Uresin AY; Baran E
Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():32-8. PubMed ID: 20019475
[TBL] [Abstract][Full Text] [Related]
15. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis.
Balamuthusamy S; Srinivasan L; Verma M; Adigopula S; Jalandhara N; Hathiwala S; Smith E
Am Heart J; 2008 May; 155(5):791-805. PubMed ID: 18440325
[TBL] [Abstract][Full Text] [Related]
16. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
Horký K
Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
[TBL] [Abstract][Full Text] [Related]
17. Renin-angiotensin system inhibitor and statins combination therapeutics - what have we learnt?
Koh KK; Sakuma I; Hayashi T; Kim SH; Chung WJ
Expert Opin Pharmacother; 2015 May; 16(7):949-53. PubMed ID: 25747324
[TBL] [Abstract][Full Text] [Related]
18. Of the renin-angiotensin system and reactive oxygen species Type 2 diabetes and angiotensin II inhibition.
Leiter LA; Lewanczuk RZ
Am J Hypertens; 2005 Jan; 18(1):121-8. PubMed ID: 15691626
[TBL] [Abstract][Full Text] [Related]
19. AT2 receptors in cardiovascular and renal diseases.
Kaschina E; Namsolleck P; Unger T
Pharmacol Res; 2017 Nov; 125(Pt A):39-47. PubMed ID: 28694144
[TBL] [Abstract][Full Text] [Related]
20. The sudden demise of dual renin-angiotensin system blockade or the soft science of the surrogate end point.
Messerli FH
J Am Coll Cardiol; 2009 Feb; 53(6):468-70. PubMed ID: 19195602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
